Edition:
United Kingdom

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

103.50EUR
4:37pm BST
Change (% chg)

€0.00 (+0.00%)
Prev Close
€103.50
Open
€101.90
Day's High
€105.80
Day's Low
€96.50
Volume
165,545
Avg. Vol
71,057
52-wk High
€120.50
52-wk Low
€51.48

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech 9 Month Net Profit Rises To 160.7 Million Euros
6:00am BST 

Oct 23 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9M GROUP SALES REVENUE UP 13.8%; ORDER INTAKE UP 14.5%; EARNINGS MARGIN 28.1%.2018 GUIDANCE CONFIRMED.FY SALES REVENUE GROWTH NOW PROJECTED TO BE IN UPPER RANGE OF PREVIOUSLY TARGETED BANDWIDTH OF 11% TO 14%.FY UNDERLYING EBITDA MARGIN CONTINUES TO BE EXPECTED AT AROUND 28.0%.9 MONTH NET PROFIT EUR 160.7 MILLION VERSUS EUR 130.8 MILLION YEAR AGO.9M UNDERLYING EBITDA 251.4 MILLION EUROS.  Full Article

Sartorius Stedim Biotech And Repligen Corporation Partner On Next-Gen Perfusion-Enabled Bioreactors
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH SA - SARTORIUS STEDIM BIOTECH AND REPLIGEN CORPORATION PARTNER TO INTRODUCE NEXT-GENERATION PERFUSION-ENABLED BIOREACTORS.  Full Article

Sartorius Stedim Biotech H1 Net Profit Up At 103.7 Million Euros
Tuesday, 24 Jul 2018 

July 24 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::BUSINESS FIGURES FOR THE FIRST HALF OF 2018: SARTORIUS STEDIM BIOTECH RECORDS DOUBLE-DIGIT GROWTH IN SALES AND PROFIT.H1 GROUP REVENUE UP 11.1%, ORDER INTAKE UP 11.8% AND EARNINGS(1)) UP 11.1%.IN FIRST HALF OF 2018, SALES REVENUE ROSE BY 11.1% IN CONSTANT CURRENCIES (REPORTED: +7.3%) FROM 545.9 MILLION EUROS TO 585.7 MILLION EUROS.MANAGEMENT HAS RAISED ITS FORECAST FOR FULL YEAR: IN CONSTANT CURRENCIES, SALES REVENUE IS NOW ANTICIPATED TO INCREASE BY ABOUT 11% TO 14%.FY SALES REVENUE IS NOW ANTICIPATED TO INCREASE BY ABOUT 11% TO 14% VERSUS PREVIOUS GUIDANCE OF 7% TO 10%..2018 UNDERLYING EBITDA MARGIN IS NOW PROJECTED TO REACH AROUND 28.0%.H1 NET PROFIT EUR 103.7 MILLION VERSUS EUR 89.1 MILLION YEAR AGO.H1 UNDERLYING EBITDA WAS UP BY 11.1%, FROM 146.5 MILLION EUROS TO 162.8 MILLION EUROS.H1 SALES REVENUE EUR 585.7 MILLION VERSUS EUR 546.7 MILLION YEAR AGO.  Full Article

Sartorius Stedim Biotech And Siemens Sign Long-Term Cooperation Agreement In Area Of Automation
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Sartorius Stedim Biotech Sa ::SARTORIUS STEDIM BIOTECH AND SIEMENS SIGN LONG-TERM COOPERATION AGREEMENT IN AREA OF AUTOMATION.SIEMENS BECOMES A PREFERRED SUPPLIER FOR AUTOMATION SOLUTIONS.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.  Full Article

Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros
Tuesday, 24 Apr 2018 

April 24 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::CONFIRMS 2018 TARGETS.IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS..Q1 UNDERLYING EBITDA INCREASED 3.0%, AND REACHED 74.0 MILLION EUROS.Q1 CAPEX RATIO OF 2018 WAS 9.2%.Q1 ORDER INTAKE INCREASED BY 9.0% IN CONSTANT CURRENCIES (REPORTED 3.9 PERCENT).EQUITY RATIO ET END OF PERIOD 62.8% (DEC. 31, 2017: 62.6%).Q1 EBITDA EUR 74.0 MILLION VERSUS EUR 71.9 MILLION YEAR AGO.Q1 NET PROFIT EUR 47.1 MILLION VERSUS EUR 44.0 MILLION YEAR AGO.  Full Article

Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership
Monday, 16 Apr 2018 

April 16 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY.  Full Article

Abzena Selects Sartorius Stedim Biotech To Equip Sites In San Diego And Bristol
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::ABZENA SELECTS SARTORIUS STEDIM BIOTECH TO EQUIP US BASED DVLPT AND MANUFACTURING SITES IN SAN DIEGO AND BRISTOL.TO EQUIP ABZENA INTEGRATED CDMO FACILITIES IN BRISTOL AND SAN DIEGO.EQUIP SAN DIEGO PROCESS DVLPT LAB WITH AMBR250, ENABLING FAST SCALE UP TO 500L INITIALLY AND LATER TO 2000L SCALE SINGLE-USE BIOREACTOR.WILL PROVIDE BOTH FACILITIES WITH END-TO-END PROCESS SOLUTIONS IN SINGLE-USE (SU) FORMAT.  Full Article

Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO.9 MONTHS EBITDA EUR ‍​216.2 MILLION VERSUS EUR 214.1 MILLION YEAR AGO.9 MONTHS NET PROFIT EUR 132.1‍​ MILLION VERSUS EUR 131.3 MILLION YEAR AGO.‍FULL-YEAR 2017 GUIDANCE ADJUSTED, MID-TERM OUTLOOK CONFIRMED​.‍FOR 2017 NOW EXPECTS THAT SALES REVENUE GROWTH WILL REACH APPROX. 4% IN CONSTANT CURRENCIES ​.‍FOR 2017 UNDERLYING EBITDA MARGIN WILL BE APPROX. AT PRIOR-YEAR LEVEL OF 27.5%​.FOR 2017 ‍CAPITAL EXPENDITURES ARE EXPECTED TO BE AT UPPER END OF BANDWIDTH OF AROUND 10% TO 13% OF SALES.​.  Full Article

Sartorius Stedim Biotech cuts 2017 outlook
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::REPORTED ON MONDAY 9-MONTH SALES REVENUE EUR 806 MLN, UP 3.3 PCT IN CONSTANT CURRENCIES.9-MONTH UNDERLYING EBITDA MARGIN AT 26.8 PCT VS 27.3 PCT YEAR AGO.IN 2017 SEES INCREASE OF SALES REVENUE IN CONSTANT CURRENCIES BY ABOUT 4 PCT (VS PREVIOUS GUIDANCE FROM ABOUT 8 PCT TO 12 PCT) .IN 2017 SEES UNDERLYING EBITDA MARGIN IN CONSTANT CURRENCIES AT ABOUT THE PRIOR-YEAR LEVEL OF 27.5 PCT (VS PREVIOUS GUIDANCE ABOUT +0.5 PCT POINTS VS FY 2016).CONFIRMS MID-TERM TARGETS.  Full Article

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.